Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cells

Hypertension Research

Volumn 37, Issue 5, 2014, Pages 422-431

  Mikami, Daisuke ^a   Kimura, Hideki ^a,b   Kamiyama, Kazuko ^a   Torii, Kunio ^b   Kasuno, Kenji ^a   Takahashi, Naoki ^a   Yoshida, Haruyoshi ^c   Iwano, Masayuki ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^c Obama Municipal Hospital   (Japan)

Author keywords

ERK pathway; plasminogen activator inhibitor 1; TGF beta 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITROBENZANILIDE; 3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; ALDOSTERONE; ANGIOTENSIN II; COLLAGEN TYPE 4; FATTY ACID BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; UNCOUPLING PROTEIN 2; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; FABP3 PROTEIN, HUMAN; ION CHANNEL; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN 2;

ANTIFIBROTIC EFFECT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY BIOPSY; MESANGIUM CELL; PROTEIN EXPRESSION; TRANSIENT TRANSFECTION; UPREGULATION; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; FIBROSIS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; CELL LINE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACID-BINDING PROTEINS; FIBROSIS; HUMANS; ION CHANNELS; MESANGIAL CELLS; MITOCHONDRIAL PROTEINS; PHOSPHORYLATION; PPAR DELTA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84899882008     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.157     Document Type: Article

References (46)

1. Guan Y, Breyer MD. Peroxisome proliferator-Activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30
2. Barish GD, Narkar VA, Evans RM. PPAR delta: A dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 590-597
3. Neher MD, Weckbach S, Huber-Lang MS, Stahel PF. New insights into the role of peroxisome proliferator-Activated receptors in regulating the inflammatory response after tissue injury. PPAR Res 2012; 2012: 728461
4. Stienstra R, Duval C, Muller M, Kersten S. PPARs, obesity, and inflammation. PPAR Res 2007; 2012: 95974
5. Guan Y. Peroxisome proliferator-Activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15: 2801-2815
6. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 2007; 1771: 972-982
7. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86
8. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. Transcriptional repression of atherogenic inflammation: Modulation by PPARdelta. Science 2003; 302: 453-457
9. Barroso E, Eyre E, Palomer X, Vazquez-Carrera M. The peroxisome proliferator-Activated receptor beta/delta (PPARbeta/delta) agonist GW501516 prevents TNF-Alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. Biochem Pharmacol 2011; 81: 534-543
10. Coll T, Alvarez-Guardia D, Barroso E, Gomez-Foix AM, Palomer X, Laguna JC, Vazquez-Carrera M. Activation of peroxisome proliferator-Activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells. Endocrinology 2010; 151: 1560-1569
11. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472
12. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Group LS. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003
13. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890
14. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-Angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81
15. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-Activated receptor-gamma activity. Circulation 2004; 109: 2054-2057
16. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002
17. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M. A selective peroxisome proliferator-Activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 2009; 150: 862-870
18. Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H, Yano K, Takeda K, Sunagawa K. Inhibition of tumor necrosis factor-Alpha-induced interleukin-6 expression by telmisartan through cross-Talk of peroxisome proliferator-Activated receptorgamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension 2009; 53: 798-804
19. Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-Activated receptor-gamma activation in human monocytes. J Hypertens 2012; 30: 87-96
20. Kusunoki H, Taniyama Y, Azuma J, Iekushi K, Sanada F, Otsu R, Iwabayashi M, Okayama K, Rakugi H, Morishita R. Telmisartan exerts renoprotective actions via peroxisome proliferator-Activated receptor-gamma/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension 2012; 59: 308-316
21. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, Boger RH. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55: 1159-1164
22. Yamamoto K, Ohishi M, Ho C, Kurtz TW, Rakugi H. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-Activated receptor-gamma activation. Hypertension 2009; 54: 1353-1359
23. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198: 22-28
24. Nakano A, Hattori Y, Aoki C, Jojima T, Kasai K. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-Activated receptor-gamma. Hypertens Res 2009; 32: 765-769
25. Unger T, Stoppelhaar M. Rationale for double renin-Angiotensin- Aldosterone system blockade. Am J Cardiol 2007; 100: 25J-31J.
26. Granberry MC, Hawkins JB, Franks AM. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure. Am J Health Syst Pharm 2007; 64: 931-936
27. He H, Yang D, Ma L, Luo Z, Ma S, Feng X, Cao T, Yan Z, Liu D, Tepel M, Zhu Z. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-Activated receptor-delta-dependent pathways. Hypertension 2010; 55: 869-879
28. Li L, Luo Z, Yu H, Feng X, Wang P, Chen J, Pu Y, Zhao Y, He H, Zhong J, Liu D, Zhu Z. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-Activated receptor-delta activation. Diabetes 2013; 62: 762-774
29. Toba H, Tojo C, Wang J, Noda K, Kobara M, Nakata T. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-Activated receptor-gamma in subtotal nephrectomized rat. Eur J Pharmacol 2012; 685: 91-98
30. Chen Y, Luo Q, Xiong Z, Liang W, Chen L, Xiong Z. Telmisartan counteracts TGF-beta1 induced epithelial-To-mesenchymal transition via PPAR-gamma in human proximal tubule epithelial cells. Int J Clin Exp Pathol 2012; 5: 522-529
31. Bakris G, Burgess E, Weir M, Davidai G, Koval S, Investigators AS. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364-369
32. Ladino M, Hernandez Schulman I. Renovascular and renoprotective properties of telmisartan: Clinical utility. Int J Nephrol Renovasc Dis 2010; 3: 33-38
33. Kimura H, Li X, Torii K, Okada T, Takahashi N, Fujii H, Ishihara S, Yoshida H. A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions. Nephrol Dial Transplant 2008; 23: 2496-2503
34. Ono T, Sogabe M, Ogura M, Furusaki F. Automated latex photometric immunoassay for total plasminogen activator inhibitor-1 in plasma. Clin Chem 2003; 49: 987-989
35. Hong HK, Song CY, Kim BC, Lee HS. ERK contributes to the effects of Smad signaling on oxidized LDL-induced PAI-1 expression in human mesangial cells. Transl Res 2006; 148: 171-179
36. Lim HJ, Moon I, Han K. Transcriptional cofactors exhibit differential preference toward peroxisome proliferator-Activated receptors alpha and delta in uterine cells. Endocrinology 2004; 145: 2886-2895
37. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489-503
38. Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett 2008; 582: 26-31
39. Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010; 19: 393-402
40. Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Sugimoto T, Koya D, Haneda M, Kashiwagi A, Maegawa H, Uzu T. Fenofibrate, a PPARalpha agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int 2011; 79: 871-882
41. Hamano Y, Okude T, Yokosuka O, Ogawa M. Attenuation of immune-mediated renal injury by telmisartan, an angiotensin receptor blocker and a selective PPAR-gamma activator. Nephron Extra 2011; 1: 78-90
42. Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005; 20: 2670-2680
43. Villa L, Boor P, Konieczny A, Kunter U, van Roeyen CR, Denecke B, Gan L, Neusser MA, Cohen CD, Consortium E, Eitner F, Scholl T, Ostendorf T, Floege J. Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: New insights into mechanisms. J Pathol 2013; 229: 672-684
44. Barroso E, Rodriguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X, Vazquez-Carrera M. The PPARbeta/delta activator GW501516 prevents the downregulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation. Endocrinology 2011; 152: 1848-1859
45. Rodriguez-Calvo R, Serrano L, Coll T, Moullan N, Sanchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vazquez-Carrera M. Activation of peroxisome proliferator-Activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 2008; 57: 2149-2157
46. Yan Z, Ni Y, Wang P, Chen J, He H, Sun J, Cao T, Chen J, Zhao Z, Luo Z, Chen L, Liu D, Zhu Z. Peroxisome proliferator-Activated receptor delta protects against obesity-related glomerulopathy through the P38 MAPK pathway. Obesity 2013; 21: 538-545